日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluation of US oncology electronic health record real-world data to reduce uncertainty in health technology appraisals: a retrospective cohort study

利用美国肿瘤电子健康记录真实世界数据评估降低卫生技术评价的不确定性:一项回顾性队列研究

Mpofu, Philani; Kent, Seamus; Jónsson, Páll; Pittell, Harlan; Groves, Brad; Altomare, Ivy; Copeland, Amanda; Baxi, Shrujal; Bargo, Danielle; Sujenthiran, Arun; Adamson, Blythe

Time from diagnosis to 2nd treatment is a promising surrogate for overall survival in patients with advanced stage follicular lymphoma

从确诊到第二次治疗的时间间隔是晚期滤泡性淋巴瘤患者总生存期的一个有希望的替代指标。

Soumerai, Jacob D; Ni, Andy; Alperovich, Anna; Batlevi, Connie; Bantilan, Kurt S; Fischer, Thais; Copeland, Amanda R; Smith, Katy; Ying, Zhitao; Younes, Anas; Zelenetz, Andrew D

Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

利用临床检测方法对弥漫性大B细胞淋巴瘤进行整合DNA/RNA靶向基因组分析

Intlekofer, Andrew M; Joffe, Erel; Batlevi, Connie L; Hilden, Patrick; He, Jie; Seshan, Venkatraman E; Zelenetz, Andrew D; Palomba, M Lia; Moskowitz, Craig H; Portlock, Carol; Straus, David J; Noy, Ariela; Horwitz, Steven M; Gerecitano, John F; Moskowitz, Alison; Hamlin, Paul; Matasar, Matthew J; Kumar, Anita; van den Brink, Marcel R; Knapp, Kristina M; Pichardo, Janine D; Nahas, Michelle K; Trabucco, Sally E; Mughal, Tariq; Copeland, Amanda R; Papaemmanuil, Elli; Moarii, Mathai; Levine, Ross L; Dogan, Ahmet; Miller, Vincent A; Younes, Anas

A phase 2 study of mocetinostat, a histone deacetylase inhibitor, in relapsed or refractory lymphoma

一项针对复发或难治性淋巴瘤的莫西替诺司他(一种组蛋白去乙酰化酶抑制剂)的 II 期研究

Batlevi, Connie L; Crump, Michael; Andreadis, Charalambos; Rizzieri, David; Assouline, Sarit E; Fox, Susan; van der Jagt, Richard H C; Copeland, Amanda; Potvin, Diane; Chao, Richard; Younes, Anas

ENGAGE- 501: phase II study of entinostat (SNDX-275) in relapsed and refractory Hodgkin lymphoma.

ENGAGE-501:恩替诺司他(SNDX-275)治疗复发和难治性霍奇金淋巴瘤的 II 期研究

Batlevi Connie Lee, Kasamon Yvette, Bociek R Gregory, Lee Peter, Gore Lia, Copeland Amanda, Sorensen Rachel, Ordentlich Peter, Cruickshank Scott, Kunkel Lori, Buglio Daniela, Hernandez-Ilizaliturri Francisco, Younes Anas

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

AKT抑制剂MK2206治疗复发或难治性淋巴瘤患者的II期研究

Oki, Yasuhiro; Fanale, Michelle; Romaguera, Jorge; Fayad, Luis; Fowler, Nathan; Copeland, Amanda; Samaniego, Felipe; Kwak, Larry W; Neelapu, Sattva; Wang, Michael; Feng, Lei; Younes, Anas

Phase I study of a novel oral Janus kinase 2 inhibitor, SB1518, in patients with relapsed lymphoma: evidence of clinical and biologic activity in multiple lymphoma subtypes

一项针对复发性淋巴瘤患者的新型口服 Janus 激酶 2 抑制剂 SB1518 的 I 期研究:在多种淋巴瘤亚型中显示出临床和生物学活性

Younes, Anas; Romaguera, Jorge; Fanale, Michelle; McLaughlin, Peter; Hagemeister, Frederick; Copeland, Amanda; Neelapu, Sattva; Kwak, Larry; Shah, Jatin; de Castro Faria, Silvana; Hart, Stefan; Wood, Jeanette; Jayaraman, Ramesh; Ethirajulu, Kantharaj; Zhu, Joy

Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/refractory B-cell lymphoma

一项针对复发/难治性B细胞淋巴瘤患者的抗CD19美登素类免疫偶联物SAR3419的多剂量递增I期研究,该药物每3周静脉输注一次。

Younes, Anas; Kim, Stella; Romaguera, Jorge; Copeland, Amanda; Farial, Silvana de Castro; Kwak, Larry W; Fayad, Luis; Hagemeister, Frederick; Fanale, Michelle; Neelapu, Sattva; Lambert, John M; Morariu-Zamfir, Rodica; Payrard, Sandrine; Gordon, Leo I

Improving T-cell therapy for relapsed EBV-negative Hodgkin lymphoma by targeting upregulated MAGE-A4

通过靶向上调的MAGE-A4改善复发性EBV阴性霍奇金淋巴瘤的T细胞疗法

Cruz, Conrad R; Gerdemann, Ulrike; Leen, Ann M; Shafer, Jessica A; Ku, Stephanie; Tzou, Benjamin; Horton, Terzah M; Sheehan, Andrea; Copeland, Amanda; Younes, Anas; Rooney, Cliona M; Heslop, Helen E; Bollard, Catherine M